Health

European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug

The EU’s Medicines Agency (EMA) rejects market authorisation for early intervention Alzheimer’s treatment Leqembi (lecanemab) due to concerns over side-effects.

Content-Type:

News Based on facts, either observed and verified directly by the reporter, or reported and verified from knowledgeable sources.

Neurons in Alzheimer's disease. 3D illustration showing amyloid plaques in brain tissue, neurofibrillary tangles and distruction of neuronal networks © Shutterstock

Catherine Feore Euractiv 29-07-2024 17:11 3 min. read Content type: News Euractiv is part of the Trust Project
Share
Facebook X LinkedIn Mail

Languages: Français | Deutsch | Polski

Donec et orci aliquet nisl suscipit molestie sed sit amet tortor. Duis vel urna ac mi sollicitudin lacinia mollis sit amet lorem. Sed finibus erat nec libero scelerisque fringilla. Morbi at orci sed urna vulputate vulputate. Nulla facilisi. Donec et orci aliquet nisl suscipit molestie sed sit amet tortor.

Want to keep reading?

Get a subscription on Euractiv Pro and elevate your political insight!

Discover Euractiv Pro
For corporations

Updated: 02-10-2024

Topics  

More from this section

Energy, Environment & Transport

‘Once-in-a-generation’ revision of clean air laws passed by EU Council

15/10/2024

3 min. read

Health

Ending HIV in Europe by 2030 requires more impetus, more investment

15/10/2024

7 min. read

Health

Dedicated EP health committee would be a step in the right direction, says Polish MEP Jarubas

14/10/2024

5 min. read

More from this author

Health

French politicians alarmed by sale of major consumer healthcare firm to US equity firm

14/10/2024

2 min. read

Health

Questions for Health Commissioner-designate Olivér Várhelyi

09/10/2024

4 min. read

Health

Mpox vaccine for adolescents and eight new medicines receive EMA approval 

20/09/2024

2 min. read

Subscribe to our newsletters

Subscribe